^
    Back
    Association details:
    Biomarker:BCR-ABL1 T315I
    Cancer:Chronic Myeloid Leukemia
    Drug:KF-1601 (Bcr-abl tyrosine kinase inhibitor, FLT3 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    ASH 2023
    Title:

    KF1601, a Novel Orally Bioavailable Inhibitor of BCR-ABL1 T315I without Inducing Thrombotic Microangiopathy

    Published date:
    11/02/2023
    Excerpt:
    In murine models using Ba/F3 Bcr-Abl T315I cell line, it showed promising in vivo antitumor efficacy, comparable to that of ponatinib…
    DOI:
    https://doi.org/10.1182/blood-2023-190891